Bioclinica Medical Imaging Achieves Milestone with Celebration of Primary Endpoint Data Analysis Contributions to 200 FDA Approvals
Bioclinica Medical Imaging, the world leader in centralized imaging services for clinical trials, announced today that it has reached a milestone in the company's history.
PRINCETON, N.J., Nov. 14, 2019 /PRNewswire-PRWeb/ -- Bioclinica Medical Imaging, the world leader in centralized imaging services for clinical trials, announced today that it has reached a milestone in the company's history: the company has contributed reliable data to the primary efficacy endpoint in more than 200 regulatory submissions from biopharmaceutical clients for therapies and indications subsequently approved by the U.S. Food and Drug Administration.
"At Bioclinica, we are proud to have played a part in helping our clients assess the safety and efficacy of new treatments that improve people's lives," said David Herron, President & CEO of Bioclinica. "We are grateful to our scientific and project teams, and to all the patients and their families who participated in the clinical studies."
Bioclinica provides science and technology expertise to assist the life science industry in advancing the development of medical therapies through services in Medical Imaging, Drug Safety Solutions, and Software Solutions. Bioclinica Medical Imaging provides comprehensive support across multiple therapeutic areas, with particular expertise in oncology, musculoskeletal, cardiovascular, gastrointestinal, neuroscience, endocrinology, infectious and respiratory disease.
"Every day, Bioclinica's team of professionals works to ensure the quality and integrity of the data we process, ensuring that our clients and regulatory authorities have information they can rely upon to evaluate the safety and efficacy of investigational treatments," said Todd Kisner, Senior Vice President, Quality Assurance & Regulatory Compliance. "We look forward to continuing to partner with the biopharmaceutical industry as the pace of innovation accelerates and the demand for high-quality image and clinical data analysis combined with regulatory expertise increases."
About Bioclinica
Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica's experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance and trial management. The company's thousands of employees serve more than 500 pharmaceutical, biotechnology and device organizations – including all top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.
Learn more about Bioclinica at http://www.Bioclinica.com. Follow the latest company news and happenings on LinkedIn and Twitter.
SOURCE Bioclinica
Share this article